Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
43 μM for BRD4(1)
4-dihydroxyoxolan-2-yl]methyl [({[({[(2R
ClH/c22-6-7-29-8-9-30-10-11-31-12-13-32-16-3-1-2-14-18(16)21(28)24(20(14)27)15-4-5-17(25)23-19(15)26
The onset of hearing impairment generally occurred during the fourth week of kanamycin dosage although the earliest onset was towards the end of the second week
(2012) Proc Natl Acad Sci U S A
PS10 aptomycin 43 μM for BRD4(1)PS10 is a novel, potent and ATP competitive pan PDK inhibitor, inhibits all PDK isoforms with IC50 of 0. 8 M, 0. 76 M, 2. 1 M and 21. 3 M for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 M). PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy. PDK: pyruvate